Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

ClinicalTrials.gov ID: NCT00781456

Public ClinicalTrials.gov record NCT00781456. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo For the Management of Menstrually-Related Migraine Headaches.

Study identification

NCT ID
NCT00781456
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Duramed Research
Industry
Enrollment
109 participants

Conditions and interventions

Conditions

Interventions

  • 91-day Levonorgestrel Oral Contraceptive Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 34 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2008
Primary completion
Jul 31, 2011
Completion
Jul 31, 2011
Last update posted
Feb 5, 2017

2009 – 2011

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
Teva Investigational Site La Mesa California 91942
Duramed Investigational Site San Diego California 92108
Teva Investigational Site San Diego California 92123
Duramed Investigational Site San Francisco California 94109-4841
Duramed Investigational Site Washington D.C. District of Columbia 20036
Duramed Investigational Site West Palm Beach Florida 33409
Teva Investigational Site Savannah Georgia 31406
Duramed Investigational Site Edison New Jersey 08817
Duramed Investigational Site New York New York 10022
Teva Investigational Site Winston-Salem North Carolina 27103
Teva Investigational Site Tulsa Oklahoma 74105
Teva Investigational Site Medford Oregon 97504
Duramed Investigational Site Philadelphia Pennsylvania 19114
Teva Investigational Site Uniontown Pennsylvania 15401
Teva Investigational Site Columbia South Carolina 29201
Teva Investigational Site Hilton Head South Carolina 29926
Teva Investigational Site Memphis Tennessee 38120
Duramed Investigational Site Dallas Texas 75234
Teva Investigational Site Houston Texas 77054
Duramed Investigational Site San Antonio Texas 78258
Duramed Investigational Site Virginia Beach Virginia 23454
Duramed Investigational Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00781456, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00781456 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →